Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABOS NASDAQ:ALLO NASDAQ:CRMD NASDAQ:SPRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$2.13-1.8%$2.40$1.19▼$3.60$153.85M0.34639,258 shs226,088 shsALLOAllogene Therapeutics$1.74-4.4%$1.99$0.98▼$4.46$600.57M0.469.10 million shs4.86 million shsCRMDCorMedix$7.87-2.2%$8.36$6.13▼$14.96$617.42M1.481.08 million shs625,282 shsSPRYARS Pharmaceuticals$5.94-1.0%$8.39$5.76▼$18.63$589.86M0.951.99 million shs3.48 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals0.00%-5.33%-3.62%-17.12%+26.79%ALLOAllogene Therapeutics0.00%-2.79%-15.53%-24.68%+4.82%CRMDCorMedix0.00%-6.53%+1.94%+6.06%-32.27%SPRYARS Pharmaceuticals0.00%-15.14%-25.94%-28.35%-67.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$2.13-1.8%$2.40$1.19▼$3.60$153.85M0.34639,258 shs226,088 shsALLOAllogene Therapeutics$1.74-4.4%$1.99$0.98▼$4.46$600.57M0.469.10 million shs4.86 million shsCRMDCorMedix$7.87-2.2%$8.36$6.13▼$14.96$617.42M1.481.08 million shs625,282 shsSPRYARS Pharmaceuticals$5.94-1.0%$8.39$5.76▼$18.63$589.86M0.951.99 million shs3.48 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals0.00%-5.33%-3.62%-17.12%+26.79%ALLOAllogene Therapeutics0.00%-2.79%-15.53%-24.68%+4.82%CRMDCorMedix0.00%-6.53%+1.94%+6.06%-32.27%SPRYARS Pharmaceuticals0.00%-15.14%-25.94%-28.35%-67.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABOSAcumen Pharmaceuticals 2.33Hold$8.00275.59% UpsideALLOAllogene Therapeutics 2.69Moderate Buy$8.52389.78% UpsideCRMDCorMedix 2.75Moderate Buy$14.8688.78% UpsideSPRYARS Pharmaceuticals 2.50Moderate Buy$28.20374.75% UpsideCurrent Analyst Ratings BreakdownLatest ABOS, ALLO, CRMD, and SPRY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/7/2026CRMDCorMedix Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$14.00 ➝ $13.007/6/2026ABOSAcumen Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/25/2026SPRYARS Pharmaceuticals Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$25.00 ➝ $24.006/1/2026SPRYARS Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/28/2026SPRYARS Pharmaceuticals Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$12.00 ➝ $30.005/15/2026SPRYARS Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026CRMDCorMedix Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/14/2026CRMDCorMedix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)5/1/2026ALLOAllogene Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/28/2026CRMDCorMedix Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$13.00 ➝ $14.004/28/2026CRMDCorMedix Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$19.00(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABOSAcumen PharmaceuticalsN/AN/AN/AN/A$1.16 per shareN/AALLOAllogene Therapeutics$20K30,028.05N/AN/A$1.30 per share1.34CRMDCorMedix$311.71M1.98$2.04 per share3.85$5.14 per share1.53SPRYARS Pharmaceuticals$84.28M7.00N/AN/A$1.16 per share5.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABOSAcumen Pharmaceuticals-$121.33M-$1.86N/AN/AN/AN/A-123.07%-79.41%8/11/2026 (Estimated)ALLOAllogene Therapeutics-$190.89M-$0.77N/AN/AN/AN/A-56.45%-40.36%8/12/2026 (Estimated)CRMDCorMedix$163.05M$2.133.69787.00N/A45.25%45.57%24.76%8/6/2026 (Estimated)SPRYARS Pharmaceuticals-$171.30M-$2.01N/AN/AN/A-200.00%-153.61%-60.85%8/12/2026 (Estimated)Latest ABOS, ALLO, CRMD, and SPRY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2026Q2 2026ALLOAllogene Therapeutics-$0.16N/AN/AN/A$0.00 millionN/A8/12/2026Q2 2026SPRYARS Pharmaceuticals-$0.4766N/AN/AN/A$31.33 millionN/A8/11/2026Q2 2026ABOSAcumen Pharmaceuticals-$0.39N/AN/AN/AN/AN/A8/6/2026Q2 2026CRMDCorMedix$0.26N/AN/AN/A$96.04 millionN/A5/15/2026Q1 2026SPRYARS Pharmaceuticals-$0.53-$0.61-$0.08-$0.61$22.20 million$22.68 million5/14/2026Q1 2026CRMDCorMedix$0.35$0.43+$0.08$0.43$104.96 million$127.43 million5/13/2026Q1 2026ALLOAllogene Therapeutics-$0.19-$0.18+$0.01-$0.18$0.00 millionN/A5/12/2026Q1 2026ABOSAcumen Pharmaceuticals-$0.4028-$0.33+$0.0728-$0.33N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABOSAcumen PharmaceuticalsN/AN/AN/AN/AN/AALLOAllogene TherapeuticsN/AN/AN/AN/AN/ACRMDCorMedixN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABOSAcumen Pharmaceuticals0.194.554.55ALLOAllogene TherapeuticsN/A9.659.65CRMDCorMedix0.332.972.74SPRYARS Pharmaceuticals2.794.944.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABOSAcumen Pharmaceuticals71.01%ALLOAllogene Therapeutics83.63%CRMDCorMedix34.18%SPRYARS Pharmaceuticals68.16%Insider OwnershipCompanyInsider OwnershipABOSAcumen Pharmaceuticals10.20%ALLOAllogene Therapeutics13.20%CRMDCorMedix3.50%SPRYARS Pharmaceuticals33.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABOSAcumen Pharmaceuticals2072.23 million64.86 millionOptionableALLOAllogene Therapeutics310345.15 million299.60 millionOptionableCRMDCorMedix3078.45 million75.71 millionOptionableSPRYARS Pharmaceuticals9099.30 million65.74 millionOptionableABOS, ALLO, CRMD, and SPRY HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRYJuly 23 at 10:00 AM | prnewswire.comLevin Capital Strategies L.P. Has $4.44 Million Holdings in ARS Pharmaceuticals, Inc. $SPRYJuly 23 at 5:44 AM | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of "Moderate Buy" by AnalystsJuly 23 at 3:15 AM | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRYJuly 21, 2026 | globenewswire.comARS Pharmaceuticals (NASDAQ:SPRY) Sets New 52-Week Low - Time to Sell?July 20, 2026 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 5.2% - Time to Sell?July 19, 2026 | americanbankingnews.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Average Recommendation of "Moderate Buy" from BrokeragesJuly 18, 2026 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 5.2% - Here's WhyJuly 17, 2026 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRYJuly 16, 2026 | prnewswire.comARS Pharmaceuticals (SPRY) Appoints Donn Casale As The New CEOJuly 15, 2026 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRYJuly 14, 2026 | globenewswire.comGeneral American Investors Co. Inc. Buys 167,195 Shares of ARS Pharmaceuticals, Inc. $SPRYJuly 12, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Stevanato Group (STVN) and ARS Pharmaceuticals (SPRY)July 11, 2026 | theglobeandmail.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRYJuly 9, 2026 | prnewswire.comCan ARS Pharma's New CEO Unlock Neffy's Potential?July 9, 2026 | benzinga.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRYJuly 7, 2026 | globenewswire.comARS Pharmaceuticals appoints Donn Casale as CEOJuly 7, 2026 | tipranks.comARS Pharmaceuticals Announces CEO SuccessionJuly 7, 2026 | globenewswire.comARS Pharmaceuticals (SPRY) Securities Fraud Investigation - Levi & KorsinskyJuly 6, 2026 | prnewswire.comSPRY Investor Alert: Levi & Korsinsky Investigates ARS Pharmaceuticals (SPRY) for Potential Securities FraudJuly 1, 2026 | tmcnet.comJanney Montgomery Scott LLC Has $16.19 Million Position in ARS Pharmaceuticals, Inc. $SPRYJuly 1, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026Rocket Lab’s Stock Drop Comes With a Bullish TwistBy Ryan Hasson | July 10, 2026AirJoule Unveils Prime System, Clearing Path to CommercializationBy Thomas Hughes | July 1, 2026AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space SectorBy Jessica Mitacek | July 17, 2026ABOS, ALLO, CRMD, and SPRY Company DescriptionsAcumen Pharmaceuticals NASDAQ:ABOS$2.13 -0.04 (-1.84%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$2.12 0.00 (-0.23%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.Allogene Therapeutics NASDAQ:ALLO$1.74 -0.08 (-4.40%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.74 0.00 (-0.29%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.CorMedix NASDAQ:CRMD$7.87 -0.18 (-2.24%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$7.87 0.00 (0.00%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.ARS Pharmaceuticals NASDAQ:SPRY$5.94 -0.06 (-1.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$6.04 +0.11 (+1.77%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
